Impact BioMedical, Inc.

Impact BioMedical Inc. discovers, develops, and commercializes products and technologies for unmet needs in human healthcare and wellness, focusing on specialty biopharmaceuticals, antivirals, antimicrobials, and consumer healthcare in the United States. Its offerings include Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds for oncology, inflammatory disorders, and neurology; Laetose, a technology derived from a combination of sugar and inositol that may inhibit the inflammatory and metabolic response of sugar alone; and functional fragrance formulations containing botanical ingredients for antimicrobial use and as additives in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. The company also develops Equivir/Equivir G, a blend of polyphenols with demonstrated antiviral effects for health supplements and medications, and is developing 3F, a formulation of botanical ingredients. Incorporated in 2018 and based in Houston, Texas, Impact BioMedical Inc. operates as a subsidiary of DSS BioHealth Security, Inc.